Академический Документы
Профессиональный Документы
Культура Документы
Currently, PF sells 200 chairs per month. Each chair sells at an average price of
€100. Below are the forecasted fixed and variable costs for 2019.
Table 1: Fixed costs
1c. Construct a fully labelled break-even chart, to scale, for PF for 2019. [4 marks]
1d. Calculate the forecasted profit if PF sells 2400 chairs in 2019 (show all [2 marks]
your working).
Copper Health (CH)
Copper Health (CH) was the market leader in the production of anti-venom*
vaccines to treat poisonous snake bites. CH’s mission – influenced heavily by
corporate social responsibility (CSR) – is to put customers first and profits second
in the treatment of snake bites.
Despite 100 000 deaths worldwide each year from snake bites and 400 000
serious injuries, CH recently announced that it will no longer produce anti-venom
vaccines. Several large Mexican, Brazilian and Indian pharmaceutical companies
have entered the market selling anti-venom vaccines at a much lower price than
CH.
A spokesperson for CH said: “We will remain a private limited company where
corporate social responsibility (CSR) remains an important driving force for our
mission. Our medical research is only financed from retained profit. When the
lower-priced competition arrived, our sales and profits of anti-venom vaccines
decreased significantly. Treating snakebites no longer makes financial sense.
Instead, the technology used to produce anti-venom vaccines will be used to
research and develop (R&D) other life-saving vaccines”.
A non-governmental organization (NGO) has demanded action. “CH is the largest
manufacturer of anti-venom vaccines in the world. Although CH’s competitors are
increasing their production of anti-venom vaccines they will not be able to
produce enough to satisfy demand for the next two years. There will be a major
shortage. This will result in many life-threatening injuries and deaths.”
The non-governmental organization (NGO) has urged CH to seek new sources of
finance to continue the production of the anti-venom vaccine.
[Source: © International Baccalaureate Organization 2019]
* anti-venom: a medication made from antibodies that is used to treat venomous
bites and stings
2c. Explain two possible external sources of finance CH could use to [4 marks]
continue production of anti-venom vaccines.
2d. Discuss CH’s decision to stop producing anti-venom vaccines. [10 marks]
(c) Using Table 1 and your calculations in (i) and (ii), construct a profit and loss
account for PI.
3c. Using Table 2, calculate the net cash flow (Z) for PI for 2019 (show all [2 marks]
your working).
3d. Explain the difference between profit and cash flow. [2 marks]
4b. Calculate the net profit margins for DH for 2016 and 2017. [2 marks]
4c. Calculate net current assets (working capital) for DH for 2016 and 2017. [2 marks]
4d. Explain one method of above-the-line promotion and one method of [4 marks]
below-the-line promotion that DH could use to raise consumer
awareness that it is a socially responsible company.
4e. Discuss DH’s decision to develop a policy of corporate social [10 marks]
responsibility (CSR).
Papel
Papel manufactures and sells paper bags. It pays cash for 80 % of its raw
materials but, to remain competitive, it must sell on credit to all customers. Many
debtors are not paying on time and creditors (suppliers) are increasing. The board
of directors is concerned about Papel’s liquidity position.
The finance manager has provided information from Papel’s accounts.
Table 1: Selected information from Papel’s accounts at 31 October 2018
5d. Explain one possible strategy, other than elimination of credit sales, [2 marks]
for Papel to improve its liquidity position.
Visionary Toys (VT)
Visionary Toys (VT) produces highly innovative toys for children. VT began
operation in January 2017 and its unique selling point/proposition (USP) is
producing toy parts with a 3D printer. The financial director presented financial
information for VT at the end of 2017. He was concerned about VT’s liquidity.
Table 1: Revenue and expense information for the year 2017 and balance
sheet items at 31 December 2017
6c. Calculate the acid test (quick) ratio for VT for 2018. [1 mark]
7a. State any two stages of the working capital cycle. [2 marks]
7b. Calculate for GT: [2 marks]
the payback period for the €44 million investment in new equipment based on the
forecasted increase in net cash flow (show all your working).
9a. Outline two appropriate external short-term sources of finance for [2 marks]
Anubis other than loans from family and friends.
9b. Using the information above, prepare a fully labelled cash-flow forecast [5 marks]
for Anubis from January to March 2018.
9c. Comment on the predicted cash flow for Anubis for 2018. [3 marks]